{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sensitive+Skin&page=10", "query": { "condition": "Sensitive Skin", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 1053, "total_pages": 106, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sensitive+Skin&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sensitive+Skin&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T14:41:40.469Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00203268", "title": "A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "dihydroergotamine mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 13, "start_date": "2003-12", "completion_date": "2005-03", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-11-11T14:41:40.469Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00203268" }, { "nct_id": "NCT04626297", "title": "A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 254, "start_date": "2020-11-17", "completion_date": "2022-09-30", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-11-11T14:41:40.469Z", "location_count": 85, "location_summary": "Birmingham, Alabama • Hot Springs, Arkansas • North Little Rock, Arkansas + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04626297" }, { "nct_id": "NCT05535738", "title": "Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Skin Inflammation", "Allergic Contact Dermatitis" ], "interventions": [ { "name": "Squaric Acid Dibutyl Ester", "type": "DRUG" }, { "name": "Known patch test allergens", "type": "OTHER" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Guselkumab", "type": "DRUG" }, { "name": "Canakinumab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Triamcinolone Acetonide", "type": "DRUG" }, { "name": "Betamethasone Valerate", "type": "DRUG" }, { "name": "Fluticasone Propionate", "type": "DRUG" }, { "name": "Microneedle", "type": "DEVICE" }, { "name": "Suction blistering", "type": "DEVICE" }, { "name": "Skin punch biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "DEVICE", "PROCEDURE" ], "sponsor": "Wei-Che Ko", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2022-11-15", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-11-11T14:41:40.469Z", "location_count": 1, "location_summary": "Worcester, Massachusetts", "locations": [ { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05535738" }, { "nct_id": "NCT05387707", "title": "Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pruritus", "Atopic Dermatitis" ], "interventions": [ { "name": "difelikefalin 0.25 mg", "type": "DRUG" }, { "name": "difelikefalin 0.5 mg", "type": "DRUG" }, { "name": "TCS Cream", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cara Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 287, "start_date": "2022-08-16", "completion_date": "2024-02-02", "has_results": false, "last_update_posted_date": "2024-02-22", "last_synced_at": "2026-11-11T14:41:40.469Z", "location_count": 61, "location_summary": "Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Lomita", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05387707" }, { "nct_id": "NCT01457430", "title": "Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hereditary Angioedema" ], "interventions": [ { "name": "Icatibant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2011-12", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2016-10-18", "last_synced_at": "2026-11-11T14:41:40.469Z", "location_count": 5, "location_summary": "La Jolla, California • Los Angeles, California • Wheaton, Maryland + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Wheaton", "state": "Maryland" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01457430" }, { "nct_id": "NCT07046806", "title": "Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hereditary Angioedema (HAE)", "Angioedema", "Bradykinin-mediated Angioedema", "C1 Inhibitor Deficiency" ], "interventions": [ { "name": "Deucrictibant XR tablet", "type": "DRUG" }, { "name": "Placebo comparator to XR tablet", "type": "DRUG" }, { "name": "Deucrictibant 20 mg capsule", "type": "DRUG" }, { "name": "Placebo comparator to 20 mg capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institute for Asthma and Allergy", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 10, "start_date": "2025-03-10", "completion_date": "2026-04-01", "has_results": false, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-11-11T14:41:40.469Z", "location_count": 1, "location_summary": "Wheaton, Maryland", "locations": [ { "city": "Wheaton", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07046806" }, { "nct_id": "NCT05590338", "title": "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "GSK1070806", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 38, "start_date": "2022-11-04", "completion_date": "2023-12-28", "has_results": false, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-11-11T14:41:40.469Z", "location_count": 2, "location_summary": "Cypress, California • Las Vegas, Nevada", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05590338" }, { "nct_id": "NCT05155085", "title": "A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "AK002", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Allakos Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 131, "start_date": "2022-06-27", "completion_date": "2024-04-17", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-11-11T14:41:40.469Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Cullman, Alabama • Gilbert, Arizona + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05155085" }, { "nct_id": "NCT00933309", "title": "The Impact of Obesity and Obesity Treatments on Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Exemestane", "type": "DRUG" }, { "name": "Avandamet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2009-07", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2016-02-19", "last_synced_at": "2026-11-11T14:41:40.469Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00933309" }, { "nct_id": "NCT00886587", "title": "To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "F# 11054-010", "type": "DEVICE" }, { "name": "F# 10495-053", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Johnson & Johnson Consumer and Personal Products Worldwide", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "2 Years to 12 Years" }, "enrollment_count": 82, "start_date": "2009-04", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2017-05-23", "last_synced_at": "2026-11-11T14:41:40.469Z", "location_count": 2, "location_summary": "Colorado Springs, Colorado • Albuquerque, New Mexico", "locations": [ { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00886587" } ] }